Cancer‐associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Issue 5 (9th April 2019)

• Record Type: Journal Article
• Authors: Wang, Limin; Li, Xueqin; Ren, Yinghui; Geng, Hua; Zhang, Qicheng; Cao, Limin; Meng, Zhaowei; Wu, Xiang; Xu, Meilin; Xu, Ke
• Is Part Of: Cancer science. Volume 110:Issue 5(2019)
• Page Start: 1609
• Page End: 1620
• Publication Date: 2019-04-09
• Subjects: ANXA3 -- cancer‐associated fibroblast -- cisplatin -- JNK -- lung cancer; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.13998
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : Cancer tissues consist of cancer cells, surrounding stromal cells and the extracellular matrix. Cancer‐associated fibroblasts (CAF) are one of the key components of stromal cells. CAF have a great impact on the behavior of cancer cells, including proliferation, invasion, metastasis and chemoresistance in many ways. However, the underlying mechanism had not been fully elucidated. In this study, we investigated the role of CAF in cisplatin resistance of lung cancer cells. By using conditioned medium from CAF (CAF‐CM), we found that CAF decreased the sensitivity of lung cancer cells to cisplatin. RNA sequencing results showed that CAF expressed a higher level of Annexin A3 (ANXA3) than normal fibroblasts (NF), and CAF‐CM incubation increased the ANXA3 level in lung cancer cells. Overexpression of ANXA3 in lung cancer cells increased cisplatin resistance and activated c‐jun N‐terminal kinase (JNK), whereas knockdown of ANXA3 increased cisplatin sensitivity. Further study showed that CAF‐CM enhanced cisplatin resistance by inhibiting cisplatin‐induced apoptosis, determined by repression of caspase‐3 and caspase‐8, through activation of the ANXA3/JNK pathway. Conversely, suppression of JNK activation by specific inhibitor retarded the effect of CAF‐CM and ANXA3 on cisplatin sensitivity. Taken together, our study demonstrated that CAF potentiated chemoresistance of lung cancer cells through a novel ANXA3/JNK pathway both in vitro and in vivo, suggesting ANXA3 could be a potential therapeutic target for the treatment of chemoresistant cancer. Abstract : Cancer‐associated fibroblasts decreased the sensitivity of lung cancer cells to cisplatin. CAF expressed higher level of ANXA3 than normal fibroblasts (NF), and CAF‐CM incubation increased the ANXA3 level in lung cancer cells. CAF potentiated chemoresistance of lung cancer cells through a novel ANXA3/JNK pathway both in vitro and in vivo.